Patent · US Active

Recombinant bordetella strains

US9528086B2 · kind B2 · utility

6Cited by

2References

13Claims

0Family size

Assignees

UNIVERSITÉ DROIT ET SANTÉ LILLE II · FR
INSERM · FR
INSTITUT PASTEUR DE LILLE · FR

Inventors

Camille Locht · Wannehain, FR
Nathalie Mielcarek · Blandain, BE
Hana Kammoun · La Madeleine, FR

Key dates

Filing date	Apr 9, 2015
Grant date	Dec 27, 2016
Priority date	—
Expiry date	Apr 9, 2035

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A genetically attenuated Bordetella pertussis strain includes a mutated pertussis toxin (ptx) gene, and a heterologous ampG gene, and a hybrid protein including the N-terminal fragment of filamentous haemagglutinin (FHA) and a heterologous epitope or antigenic protein or protein fragment, different from FHA. The strain can be used in an attenuated vaccine for the treatment or prophylaxis of an infectious disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.